GD2-Targeted Minibody-Drug Conjugates Match the Potency of IgG-Based ADCs in a Mouse Cancer Model.

Daniel V Kalinovsky, Matvey M Titov, Irina V Kholodenko, Alexey V Kibardin, Elena V Svirshchevskaya, Sergey M Deyev, Roman V Kholodenko

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daniel V KalinovskyShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.ORCID 0000-0001-8773-2797

Matvey M TitovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.

Irina V KholodenkoOrekhovich Institute of Biomedical Chemistry, Moscow 119121, Russia.ORCID 0000-0002-4079-5210

Alexey V KibardinD. Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Moscow 117997, Russia.

Elena V SvirshchevskayaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.

Sergey M DeyevShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.ORCID 0000-0002-3952-0631

Roman V KholodenkoShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.ORCID 0000-0001-6083-6588

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2024-536

6 · The paper itself

Abstract

Despite the clinical success of antibody-drug conjugates (ADCs), their efficacy in solid tumors remains constrained by limited tumor penetration of the IgG format. Smaller antibody fragment-drug conjugates (FDCs) present a compelling alternative, potentially offering superior intratumoral distribution and a wider therapeutic window driven by rapid systemic clearance. This study compares therapeutic activity of ganglioside GD2-specific minibody-drug conjugates against full-length ch14.18 antibody-drug conjugates, and biodistribution of the respective minibody (scFv-C

Indexed as

GangliosidesImmunoconjugatesImmunoglobulin GAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansMiceTissue Distributionganglioside, GD2GangliosidesImmunoconjugatesImmunoglobulin Gantibody-drug conjugatesantibody fragment-drug conjugatesantibody fragmentscancerganglioside GD2GD2-positive tumorsimmunotherapymelanomaminibodiesneuroblastoma

Identifiers

PMID41752109

DOI10.3390/ijms27041974

PMCPMC12940281

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.